Download this Infographic to Learn More
Discover what’s shaping early-phase oncology in the white paper: Early-Phase Oncology – Clinical Research Landscape and CRO Enablers
This paper provides a snapshot of the market and provides insights on why ~60% of agents advance from Phase I to II while only 3–6% reach approval, and what sponsors can do earlier in development to improve those outcomes. It also outlines Australia’s position as a first-in-human hub and describes how programs can be efficiently expanded into the US, Europe, and broader Asia.
What you’ll learn
- Global early-phase oncology landscape and investment trends.
- Emerging trial designs: adaptive, biomarker-driven, decentralized.
- Regulatory shifts, including FDA Project Optimus and dose optimization.
- CRO enablers across feasibility, start-up, site engagement, and biometrics—supported by access to 7,260 sites.
Offered Free by: Novotech
See All Resources from: Novotech
